Advanced search
Publication Cover
Journal of Medical Economics Volume 23, 2020 - Issue 11
Submit an article Journal homepage
5,046
Views
10
CrossRef citations to date
0
Altmetric
Special Section: Pricing Methods in Outcome-Based Contracting: The Six Delta Platform : Methods and Modeling

The six Delta platform for outcome-based contracting for pharmaceuticals

Nimer S. Alkhatiba Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona, Tucson, AZ, USA;b College of Pharmacy, Al-Zaytoonah University of Jordan, Amman, JordanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-5071-9257
ORCID Icon &
Ivo Abrahama Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona, Tucson, AZ, USA;c Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ, USA;d University of Arizona Cancer Center, University of Arizona, Tucson, AZ, USA;e Department of Family and Community Medicine, College of Medicine, University of Arizona, Tucson, AZUSA;f Matrix45, Tucson, AZUSAORCID Iconhttps://orcid.org/0000-0003-0490-4421
ORCID Icon
Pages 1209-1214 | Received 18 May 2020, Accepted 01 Sep 2020, Published online: 29 Sep 2020
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days
Click to increase image sizeClick to decrease image sizeFree first page
This article refers to:
Pricing methods in outcome-based contracting: integration analysis of the six dimensions (6 δs)
Pricing methods in outcome-based contracting: δ6: adherence-based pricing
Pricing methods in outcome-based contracting: δ2: willingness-to-pay-based pricing
Pricing methods in outcome-based contracting: δ1: cost effectiveness analysis and cost-utility analysis-based pricing
Pricing methods in outcome-based contracting: δ5: risk of efficacy failure-based pricing
Pricing methods in outcome-based contracting: δ4: safety-based pricing
Pricing methods in outcome-based contracting: δ3: reference-based pricing

Transparency

Declaration of funding

The work reported herein was performed without sponsorship or grant funding.

Declaration of financial/other interests

The authors have no financial relationships to declare.

JME peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Author contributions

All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript.

Acknowledgements

No assistance was received in the preparation of this article.

Notes

i Proscar is a registered trademark of Merck & Co., Inc., Kenilworth, NJ, USA.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Download PDF

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.